Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTHealth Ketamine Project
NCT02882711Phase 2Terminated
- Sponsor
- UTHealth Houston
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in major depressive disorder (MDD) and bipolar disorder (BD), sponsored by UTHealth Houston. Primary endpoint: Number of Adverse Events. Started Nov 2016; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT02882711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882711.